Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 4Lymphoid 2CNS 2Breast 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Other 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Neuroendocrine Tumors 169Carcinoid Tumor 27Carcinoma, Neuroendocrine 22Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 16Adenoma, Islet Cell 15Pancreatic Neoplasms 12Neoplasm Metastasis 10Pheochromocytoma 8Paraganglioma 8Sarcoma 7Colorectal Neoplasms 7Carcinoma 7Neuroectodermal Tumors, Primitive 6Neuroblastoma 6Gastrointestinal Neoplasms 6Vipoma 5Somatostatinoma 5Gastrinoma 5Cholangiocarcinoma 5Carcinoma, Islet Cell 5Breast Neoplasms 5Small Cell Lung Carcinoma 4Serotonin Syndrome 4Digestive System Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3

Interventions

lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypertension × NET × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡